RSS

Santhera Pharmaceuticals

Swiss specialty pharmaceutical company, Santhera Pharmaceuticals, has received a negative opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its revised marketing authorisation application for Raxone in DMD more

News

The rare disease pharmaceutical company, Santhera Pharmaceuticals, has chosen Veeva CRM and Veeva OpenData as commercial software and data platform for its first product launch. more

News

Santhera Pharmaceuticals has announced that the MHRA has granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) to Raxone (idebenone) for patients with respiratory function decline not taking glucocorticoids in DMD more

News